The state of Illinois currently has 17 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Recruiting
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: University of Chicago, Chicago, Illinois
Conditions: Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
Explanted Lung Tissues With Pulmonary Fibrosis
Recruiting
The goal of this study is to use the tissues from the explanted lungs in order to better study the cause of pulmonary fibrosis at a cellular level.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: The University of Chicago, Chicago, Illinois
Conditions: Pulmonary Fibrosis
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
Recruiting
The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: University of Chicago, Chicago, Illinois
Conditions: Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Recruiting
Acute exacerbations (AE) are a dreaded manifestation of idiopathic pulmonary fibrosis (IPF) that presents with rapidly worsening respiratory function over days to weeks. AE account for about 1/2 the deaths in IPF patients, and are refractory to all medical therapies attempted to date. Considerable preliminary data shows pathological B-cell abnormalities and autoantibodies are present in AE-IPF and associated with disease severity. The experimental therapy here (therapeutic plasma exchange plus... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
08/04/2023
Locations: Dan Dilling, Chicago, Illinois
Conditions: Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Pulmonary Fibrosis Foundation Community Registry
Recruiting
Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members. The Pulmonary Fibrosis Foundation Community Registry will offer an online portal where participants can self-enroll and directly contribute information about their experience with PF to be compiled into a longitudinal data set for use by researchers.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/28/2022
Locations: Pulmonary Fibrosis Foundation, Chicago, Illinois
Conditions: Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis, Idiopathic Pulmonary Fibrosis